Given that PCBP1 is a well-established tumor suppressor [10–18] and UBE4A is an enzyme, determination of this cross-talk in normal physiological conditions and in pathological context will be vital for rationale design of therapeutic strategy to target UBE4A expression. This evidence concerns the gene UBE4A and neoplasm.